This week, Genedata said that Axxam, a Milan, Italy-based contract research firm, has selected its Genedata Screener software to support its customers' early-stage therapeutic discovery projects.
Genedata said that Axxam will use Genedata Screener to provide tailored data analysis for customer-specific screening and hit-to-lead services.
Specifically, Axxam will use Genedata Screener's Assay Analyzer module to import and process data from screening instruments using pre-defined protocols; its Condoseo module to fit dose-response curves and optimize them for large compound sets; and its Hit Profiler module to import biological results for compounds from different data sources and display them in tabular format.
In a statement, Michela Stucchi, who heads Axxam's screening technologies division, said the firm chose Genedata's software because it provides "a flexible high-throughput screening solution " that allows users to streamline and simplify complex assays.
Furthermore, "users with basic skills can easily load and analyze data for a fast quality check," she said.
Gendata's CEO, Othmar Pfannes, described the Axxam deal as "an important milestone" in his firm's product strategy, which includes expanding its sphere of influence beyond pharmaceutical companies and into the contract research market.